A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Conditions

• Melanoma
• Breast Carcinoma
• Hepatocellular Carcinoma
• Urothelial Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Renal Cell Carcinoma
• Colorectal Carcinoma
• Non-small Cell Lung Carcinoma
• Gastric or Gastroesophageal Junction Adenocarcinoma
• Endometrial Carcinoma
• Mesothelioma
• Neuroendocrine Carcinoma
• Cervical Cancer
• Small Cell Lung Carcinoma
• Squamous Cell Carcinoma of the Anus
• Castration-Resistant Prostate Carcinoma
• Nasopharyngeal Carcinoma
• Cholangiocarcinoma
• Basal Cell Carcinoma
• Ovarian Carcinoma
• Fallopian Tube Carcinoma
• Thymoma
• Thymic Carcinoma
• Squamous Cell Carcinoma of the Penis
• Vulvar Carcinoma
• Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
• Malignant Adnexal Neoplasms
• Non-squamous Cell Salivary Gland Carcinoma

Interventions

BIOLOGICAL

XmAb20717

Monoclonal bispecific antibody

Sponsors & Collaborators

• ICON plc

  collaborator INDUSTRY

• Xencor, Inc.

  lead INDUSTRY

Principal Investigators

• Zequn Tang, MD · Xencor, Inc.

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-07-10

Primary Completion

2022-06-01

Completion

2022-09-06

FDA Drug

Yes

Countries

• United States

Study Locations